Active Ingredient: Apixaban
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Oral, 10 milligrams apixaban, 2 times daily, over the duration of 7 days. Afterwards, oral, 5 milligrams apixaban, 2 times daily.
The recommended dose of apixaban for the treatment of acute DVT and treatment of PE is 10 mg taken orally twice daily for the first 7 days followed by 5 mg taken orally twice daily. As per available medical guidelines, short duration of treatment (at least 3 months) should be based on transient risk factors (e.g., recent surgery, trauma, immobilisation).
Dose recommendation (VTEt):
| Dosing schedule | Maximum daily dose | |
| Treatment of DVT or PE | 10 mg twice daily for the first 7 days | 20 mg |
| followed by 5 mg twice daily | 10 mg |
The duration of overall therapy should be individualised after careful assessment of the treatment benefit against the risk for bleeding.
A missed morning dose should be taken immediately when it is noticed, and it may be taken together with the evening dose. A missed evening dose can only be taken during the same evening, the patient should not take two doses the next morning. The patient should continue with the intake of the regular dose twice daily as recommended on the following day.
Switching treatment from parenteral anticoagulants to apixaban (and vice versa) can be done at the next scheduled dose. These medicinal products should not be administered simultaneously.
When converting patients from vitamin K antagonist (VKA) therapy to apixaban, warfarin or other VKA therapy should be discontinued and apixaban started when the international normalised ratio (INR) is <2.
When converting patients from apixaban to VKA therapy, administration of apixaban should be continued for at least 2 days after beginning VKA therapy. After 2 days of coadministration of apixaban with VKA therapy, an INR should be obtained prior to the next scheduled dose of apixaban. Coadministration of apixaban and VKA therapy should be continued until the INR is ≥2.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.